Study Reveals Inflammation Drives Preterm Delivery for Patients With Diabetes

A retrospective study revealed a significant synergistic interaction between maternal C-reactive protein (CRP) levels and diabetes, indicating that inflammation may be a primary driver of preterm delivery risk in patients with diabetes. The research, which analyzed over 3000 singleton pregnancies, found that although elevated CRP alone did not significantly increase the risk of preterm birth in women without diabetes, the risk nearly tripled for those with diabetes who were in the highest CRP tertile.¹

“Diabetes is a well-established risk factor for PTD [preterm delivery], with studies showing that women with gestational diabetes or pre-existing diabetes are at higher risk for spontaneous PTD,” the study authors said. “Hyperglycemia induces the release of pro-inflammatory cytokines, activating inflammation-related signaling pathways that disrupt placental and uterine function, further elevating the risk of PTD.”

About The Findings

This finding highlights a clinical intersection where chronic metabolic stress meets acute peripartum inflammatory activation, creating a high-risk environment that pharmacists and obstetric teams must navigate. For pharmacists involved in prenatal care, these results suggest that monitoring accessible inflammatory markers such as CRP could provide essential insights into which patients with diabetes are most susceptible to inflammation-related pathways leading to early birth.

The biological plausibility of this interaction stems from the fact that hyperglycemia induces the release of proinflammatory cytokines, which in turn activate signaling pathways that can disrupt uterine and placental function. Women with diabetes already exhibit heightened systemic inflammation, and the addition of elevated CRP—typically measured at levels exceeding 4.7 mg/L—appears to reach a threshold where inflammatory activation becomes clinically relevant to preterm delivery risk.

“In our analysis, the increased risk of PTD was concentrated in the highest CRP tertile (> 4.7 mg/L), whereas the middle tertile showed little difference from the lowest tertile,” the study authors said.

The dual mechanism of metabolic dysfunction and inflammation is particularly concerning given that preterm birth complications remain the leading cause of death for children under five globally. Pharmacists are uniquely positioned to assist in this area by emphasizing the importance of glycemic control, as adequate management can help mitigate some of the proinflammatory pathways exacerbated by high blood sugar.^1,2

Gestational Diabetes and Health Care

The broader context of gestational diabetes mellitus (GDM) further underscores the necessity of a multidisciplinary approach, as even well-managed glycemic levels are sometimes insufficient to prevent fetal distress. Recent clinical data shows that approximately 17.72% of women diagnosed with GDM experience premature birth, often involving complications like polyhydramnios or requiring emergency caesarean sections.²

Polyhydramnios, which occurs in nearly 78% of preterm GDM cases, can cause premature rupture of membranes by putting excessive pressure on the cervix, further complicating the pharmacological and surgical management of these patients. Pharmacists must also be aware that the incidence of GDM is rising alongside global obesity rates, currently affecting about 8% of women who have a live birth in the United States.^2,3

Effective management requires intervention before, during, and after pregnancy to reduce the risk of long-term consequences for both the mother and the child. The CDC recommends that women with preexisting diabetes adjust their monitoring and medications prior to conception, a period where pharmacists can provide critical counseling on medication safety and efficacy.³

After delivery, the focus shifts to preventing the development of type 2 diabetes, as women with a history of GDM are significantly more likely to develop the condition later in life. Furthermore, children born to mothers with GDM face an increased risk of developing obesity and cardiovascular diseases as they age, emphasizing that the clinical oversight provided by the pharmacy team during pregnancy has implications that last for generations.³

The interaction between diabetes and inflammation as a risk factor for preterm delivery suggests that a one-size-fits-all approach to diabetic prenatal care may be inadequate. Although lifestyle modifications and insulin therapy remain the cornerstones of GDM management, the emerging role of inflammatory markers like CRP may signal a need for more nuanced risk assessments.^1,2

Continued research is required to determine if targeted anti-inflammatory evaluations can directly reduce the burden of preterm birth in diabetic populations. For now, pharmacists remain a vital link in the multidisciplinary chain, ensuring that glycemic control is optimized and that inflammatory risks are recognized early to improve maternal and neonatal outcomes.

READ MORE: Diabetes Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Wang N, Zhang S, Hong S, et al. Interaction between maternal CRP levels and diabetes on preterm delivery risk: a retrospective observation study. BMC Pregnancy Childbirth. Published online May 7, 2026. doi:10.1186/s12884-026-08985-7

2. Preda A, Iliescu DG, Comănescu A, et al. Gestational Diabetes and Preterm Birth: What Do We Know? Our Experience and Mini-Review of the Literature. J Clin Med. 2023;12(14):4572. Published 2023 Jul 9. doi:10.3390/jcm12144572

3. CDC. Diabetes during pregnancy. May 15, 2024. Accessed May 8, 2026. https://www.cdc.gov/maternal-infant-health/pregnancy-diabetes/index.html